Combining two types of medicine for Acute Myeloid Leukemia
Dual Kinase and LSD1 Inhibition in Acute Myeloid Leukemia
This work explores new ways to combine existing and new medicines to better treat Acute Myeloid Leukemia (AML) by targeting specific pathways in cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11110436 on NIH RePORTER |
What this research studies
We are looking into how combining two different types of medicines, called kinase inhibitors and LSD1 inhibitors, can work together to fight Acute Myeloid Leukemia. Our goal is to understand exactly how these combinations stop cancer cells from growing, particularly by affecting a gene called MYC. We hope to find out if these drug combinations can lead to more effective treatments for patients with AML, especially those with specific genetic changes like FLT3 or NRAS mutations. This involves studying the detailed mechanisms within the cancer cells to identify the best treatment strategies.
Who could benefit from this research
Good fit: This research is focused on understanding the disease and developing new treatments for patients diagnosed with Acute Myeloid Leukemia, particularly those with specific genetic mutations like FLT3 or NRAS.
Not a fit: Patients without Acute Myeloid Leukemia or those whose cancer does not involve the specific pathways being studied may not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could lead to new and more effective treatment options for patients with Acute Myeloid Leukemia, especially those who have not responded well to current therapies.
How similar studies have performed: Previous work has shown that LSD1 inhibition can enhance the effectiveness of kinase inhibitors in AML, suggesting a promising approach for further investigation.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Braun, Theodore Paul — Oregon Health & Science University
- Study coordinator: Braun, Theodore Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.